Author: Yifan Yang#1, Ran Zhang#2, Zhifang Zhong1, Jun Li#3, Yi Feng#4
Affiliation: <sup>1</sup> Department of Pain Medicine, Peking University People's Hospital, Beijing, People's Republic of China.
<sup>2</sup> Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
<sup>3</sup> Department of Pain Medicine, Peking University People's Hospital, Beijing, People's Republic of China. clivia.li@163.com.
<sup>4</sup> Department of Pain Medicine, Peking University People's Hospital, Beijing, People's Republic of China. fengyi@pkuph.edu.cn.
Conference/Journal: Neurol Sci
Date published: 2023 Dec 8
Other:
Special Notes: doi: 10.1007/s10072-023-07229-2. , Word Count: 266
Background:
Chemotherapy-induced painful peripheral neuropathy (CIPN) is a common adverse event in cancer patients, and there is still a lack of effective treatment. Transauricular vagal nerve stimulation (taVNS) is a minimally invasive treatment, but there are few reports regarding its efficacy for CIPN.
Objective:
To investigate the efficacy and possible mechanism of taVNS in patients with CIPN.
Methods:
Twenty-seven patients with CIPN were randomly divided into a taVNS group (n = 14) and a sham stimulation (SS) group (n = 13). A numerical rating scale (NRS) for pain, NCICTCAE 4.0 (neurotoxicity classification), quantitative sensory test (QST), Short-Form-Health Survey-12 (SF-12), and Athens Insomnia Scale (AIS) were administered before the intervention (D-10) and on the day after the intervention (D0), and the inflammatory cytokines in plasma were also measured. The NRS, NCI-CTCAE 4.0, SF-12, and AIS were administered again at D30 and D90.
Results:
Compared with the SS group, the NRS and AIS in the taVNS group were significantly lower at D0. The impact lasted until D30. There were no statistically significant differences in the NRS and AIS between the 2 groups at D90. On D30, the mental component score of the SF-12 was significantly higher in the taVNS group than in the SS group. No adverse events were found. There was no significant difference in QST and plasma inflammatory cytokines between the 2 groups.
Conclusion:
taVNS can relieve chemotherapy-induced neuropathic pain in the short term, can improve sleep status and quality of life, and is expected to become a novel clinical treatment method for CIPN.
Keywords: Chemotherapy-induced peripheral neuropathy (CIPN); Transauricular vagus nerve stimulation (taVNS); Vagus nerve stimulation (VNS).
PMID: 38063922 DOI: 10.1007/s10072-023-07229-2